A COVID-19 briefing with experts from the Infectious Diseases Society of America to discuss the updates to IDSA’s COVID-19 Treatment Guidelines:
- Clinical guidelines for the use of bamlanivimab
- Updates to recommendations for lopinavir/ritonavir
- Data reviews of remdesivir and tocilizumab
- What’s next in COVID-19 treatment
- Questions from the media
FEATURING:
Adarsh Bhimraj, MD, FIDSA—Cleveland, OH
Co-Chair, IDSA COVID-19 Treatment and Management Guidelines Expert Panel
Fellow, Infectious Diseases Society of America
Head of the Neurologic Infectious Diseases Section, Department of Infectious Diseases, Cleveland Clinic
Associate Staff Physician, Department of Infectious Diseases, Cleveland Clinic
Rajesh T. Gandhi, MD, FIDSA—Boston, MA
Co-Chair, IDSA COVID-19 Treatment and Management Guidelines Expert Panel
Chair, HIV Medicine Association
Professor of Medicine, Harvard Medical School
Director of HIV Clinical Services and Education, Massachusetts General Hospital
Dana Wollins, DrPH, MGC (Moderator)
Vice President, Clinical Affairs & Practice Guidelines—Infectious Diseases Society of America
